The true strength of Shockwave is a remarkable team of talented individuals with experience, creativity and tenacity. A strong leadership team is reflective of our dedication to developing technologies and applications that enable interventionalists to raise the standard of how advanced cardiovascular disease is treated.
But, right now we're in the early phases of the R&D program. In the meantime, don't miss the IVL application that heart teams are embracing already — maintaining transfemoral TAVR access through heavily calcified iliacs by using IVL.
Too bad our coronary technology is not yet approved in the United States. Good news is that we have initiated our U.S. FDA IDE study. Learn more about the Disrupt CAD III study on our clinical research portion of the website.